SERT has therefore been a central focus of pharmaceutical interest as a druggable target in the therapeutic management of affective disorders.5, 6, 7, 8 Additionally, genetic variations in the promoter region of the SERT gene have been proposed to be involved in mediating the gene × environment effects involved in the pathogenesis of depression.9, 10, 11. This evidence concerns the gene SLC6A4 and major depressive disorder.